Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study.

@article{Ringe2001AlendronateTO,
  title={Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study.},
  author={Johann Diederich Ringe and Herbert Faber and Alfred Dorst},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2001},
  volume={86 11},
  pages={5252-5}
}
Men with osteoporosis have been neglected in the past, and only a few therapeutic trials have been performed in men. The bisphosphonate, alendronate, has been widely used for the treatment of postmenopausal osteoporosis. This prospective, open label, active controlled, randomized clinical study compared the effects of oral alendronate (10 mg daily) and alfacalcidol (1 microg daily) on bone mineral density (BMD), safety, and tolerability in 134 males with primary established osteoporosis. All… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

Alendronate Treatment in Men With Primary Osteoporosis: A Three-Year Longitudinal Study

Calcified Tissue International • 2003
View 5 Excerpts
Highly Influenced

Diretrizes da Sociedade Brasileira de Reumatologia para diagnóstico e tratamento da osteoporose em homens

R. Louresa, Cristiano Augusto F. Zerbinia, +8 authors Mailze C. Bezerraa
2017

Similar Papers

Loading similar papers…